

Shunya Arai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7394049/publications.pdf>

Version: 2024-02-01

38
papers

1,044
citations

567281

15
h-index

414414

32
g-index

39
all docs

39
docs citations

39
times ranked

2239
citing authors

#	ARTICLE	IF	CITATIONS
1	Positive feedback between NF- κ B and TNF- α promotes leukemia-initiating cell capacity. <i>Journal of Clinical Investigation</i> , 2014, 124, 528-542.	8.2	184
2	Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. <i>Blood</i> , 2012, 119, 6234-6242.	1.4	143
3	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. <i>Blood</i> , 2011, 117, 3617-3628.	1.4	129
4	Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. <i>Blood</i> , 2011, 117, 6304-6314.	1.4	79
5	Recurrent CDC25C mutations drive malignant transformation in FPD/AML. <i>Nature Communications</i> , 2014, 5, 4770.	12.8	74
6	Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification. <i>Leukemia</i> , 2019, 33, 191-204.	7.2	41
7	Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. <i>Experimental Hematology</i> , 2015, 43, 849-857.	0.4	40
8	Adiponectin Enhances Antibacterial Activity of Hematopoietic Cells by Suppressing Bone Marrow Inflammation. <i>Immunity</i> , 2016, 44, 1422-1433.	14.3	37
9	JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. <i>Blood</i> , 2014, 124, 2996-3006.	1.4	36
10	Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation. <i>Stem Cells</i> , 2017, 35, 1835-1848.	3.2	34
11	ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2018, 10, 1115-1130.	4.8	29
12	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. <i>Scientific Reports</i> , 2018, 8, 15855.	3.3	24
13	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. <i>Experimental Hematology</i> , 2014, 42, 816-825.	0.4	22
14	Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan. <i>Haematologica</i> , 2018, 103, 1815-1824.	3.5	22
15	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. <i>International Journal of Hematology</i> , 2017, 106, 375-384.	1.6	17
16	Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia. <i>Blood</i> , 2014, 124, 3587-3596.	1.4	16
17	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. <i>International Journal of Hematology</i> , 2017, 105, 59-69.	1.6	13
18	Modeling of hematologic malignancies by iPSC technology. <i>Experimental Hematology</i> , 2015, 43, 654-660.	0.4	11

#	ARTICLE	IF	CITATIONS
19	A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination. <i>Leukemia</i> , 2019, 33, 1773-1782.	7.2	11
20	Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment. <i>Blood</i> , 2021, 138, 2555-2569.	1.4	10
21	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). <i>American Journal of Hematology</i> , 2017, 92, 1324-1332.	4.1	9
22	A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 788-790.	1.7	9
23	Evi-1 Is a Direct Target of MLL Oncoproteins in Hematopoietic Stem Cells. <i>Blood</i> , 2008, 112, 3807-3807.	1.4	9
24	Splenic Peliosis in a Patient with Aplastic Anemia during Danazol Therapy. <i>International Journal of Hematology</i> , 2007, 86, 329-332.	1.6	7
25	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. <i>Leukemia Research</i> , 2018, 74, 137-143.	0.8	7
26	Cyclosporine Therapy in Patients with Transfusion-independent Non-severe Aplastic Anemia: A Retrospective Analysis. <i>Internal Medicine</i> , 2019, 58, 355-360.	0.7	7
27	Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia. <i>Experimental Hematology</i> , 2021, 101-102, 42-48.e11.	0.4	6
28	Usefulness of presepsin for early detection of infections in patients with hematologic disorders. <i>Clinica Chimica Acta</i> , 2018, 486, 374-380.	1.1	3
29	Posterior reversible encephalopathy syndrome concurrent with human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 265-268.	1.7	3
30	Physical interaction between BAALC and DBN1 induces chemoresistance in leukemia. <i>Experimental Hematology</i> , 2021, 94, 31-36.	0.4	3
31	Clinical features of hematological disorders with increased large granular lymphocytes (LGLs): a retrospective study. <i>Annals of Hematology</i> , 2017, 96, 2113-2115.	1.8	2
32	The Development of Acute Systemic Multiple Thrombosis after Achieving Remission during Systemic Glucocorticoid Therapy for Acquired Hemophilia A. <i>Internal Medicine</i> , 2018, 57, 2237-2241.	0.7	2
33	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1688-1694.	1.3	2
34	CAMK2G is identified as a novel therapeutic target for myelofibrosis. <i>Blood Advances</i> , 2021, , .	5.2	2
35	Retrospective analysis on transient recurrence of steroid-sensitive acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 316-319.	2.4	1
36	Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. <i>Blood</i> , 2010, 116, 838-838.	1.4	0

#	ARTICLE	IF	CITATIONS
37	NF- κ B/TNF- α Positive Feedback Loop with Active Proteasome Machinery Supports Myeloid Leukemia Initiating Cell Capacity. Blood, 2012, 120, 654-654.	1.4	0
38	Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity In Vivo. Blood, 2019, 134, 720-720.	1.4	0